298 related articles for article (PubMed ID: 25284154)
41. Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.
Srinivas C; Swathi V; Priyanka C; Anjana Devi T; Subba Reddy BV; Janaki Ramaiah M; Bhadra U; Bhadra MP
Apoptosis; 2016 Nov; 21(11):1249-1264. PubMed ID: 27502208
[TBL] [Abstract][Full Text] [Related]
42. Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.
Zhu Z; Jiang W; McGinley JN; Thompson HJ
Cancer Prev Res (Phila); 2013 Apr; 6(4):290-8. PubMed ID: 23365133
[TBL] [Abstract][Full Text] [Related]
43. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
[TBL] [Abstract][Full Text] [Related]
44. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
45. Identification of an epigenetic signature of early mouse liver regeneration that is disrupted by Zn-HDAC inhibition.
Huang J; Schriefer AE; Yang W; Cliften PF; Rudnick DA
Epigenetics; 2014 Nov; 9(11):1521-31. PubMed ID: 25482284
[TBL] [Abstract][Full Text] [Related]
46. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
47. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
48. Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Mitsiades N; Mitsiades CS; Richardson PG; McMullan C; Poulaki V; Fanourakis G; Schlossman R; Chauhan D; Munshi NC; Hideshima T; Richon VM; Marks PA; Anderson KC
Blood; 2003 May; 101(10):4055-62. PubMed ID: 12531799
[TBL] [Abstract][Full Text] [Related]
49. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
50. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
Namdar M; Perez G; Ngo L; Marks PA
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
[TBL] [Abstract][Full Text] [Related]
51. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
[TBL] [Abstract][Full Text] [Related]
52. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
53. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
Qin Y; Zhao X; Fang Y
Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
[TBL] [Abstract][Full Text] [Related]
54. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
Sanchez-Gonzalez B; Yang H; Bueso-Ramos C; Hoshino K; Quintas-Cardama A; Richon VM; Garcia-Manero G
Blood; 2006 Aug; 108(4):1174-82. PubMed ID: 16675713
[TBL] [Abstract][Full Text] [Related]
55. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
56. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
Carbajo-García MC; García-Alcázar Z; Corachán A; Monleón J; Trelis A; Faus A; Pellicer A; Ferrero H
Fertil Steril; 2022 Feb; 117(2):433-443. PubMed ID: 34809976
[TBL] [Abstract][Full Text] [Related]
57. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo.
Dincman TA; Beare JE; Ohri SS; Gallo V; Hetman M; Whittemore SR
Int J Dev Neurosci; 2016 Nov; 54():53-61. PubMed ID: 27587342
[TBL] [Abstract][Full Text] [Related]
58. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
59. Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.
Reardon B; Beliakova-Bethell N; Spina CA; Singhania A; Margolis DM; Richman DR; Woelk CH
AIDS; 2015 Nov; 29(17):2235-44. PubMed ID: 26258524
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Mateen S; Raina K; Jain AK; Agarwal C; Chan D; Agarwal R
Epigenetics; 2012 Oct; 7(10):1161-72. PubMed ID: 22965008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
